Member Info for Hurst10

Several post market print 175/ + 75/ etc about 1,5 mill pounds worth so far on the buy side.

245/ one of the buy orders printed as timed at 17.06

245,000 bought at 260,timed at 17.06

We now have the usual afternoon size volume, which will be displayed after hours.
Would expect post the interview being displayed among overseas investors such as US buyers.
This last hour will push the stock back above 260 and then a very interesting opening tomorrow!!
We are so close to CE approval and the share price upside could be well above 300, based on some earnings est.

One should as mentioned several times today, focus on the interview discussing manufacturing partners and platform.
There are 3 signed up and as the company have indicated further UK and non UK manufacturing partners being signed.
As has been mentioned by the manufacturing partners, the UK government has participated in financial assistance, in order to increase the manufacturing capacity substantially.With CE approval about happen, further partnerships to be announced ,the testing volume and future earnings, will be substantially ahead of any forecast!!
Take advantage of a day like this !!!

Note that the house broker is best bid, clever move in order to pick up stock for afternoon buyer.

Interesting read across from today’s transaction, which again highlights how attractive the Diagnostics companies such as Avacta are to the majors.
:
Roche to Buy Covid Test Maker GenMark for $1.8 Billion

The Swiss drugmaker will pay $24.05 a share in cash, it said in a statement Monday. That’s 30% more than Friday’s closing price. The boards of both companies approved the transaction.
GenMark’s tests can detect multiple pathogens from a single patient sample. The pandemic has fueled demand for tests that can swiftly diagnose Covid-19 and other diseases, kindling a wave of deal-making in the diagnostics field. The transaction is Roche’s largest since the takeover of Spark Therapeutics Inc. in 2019.

Next picture is our PM in a white Avacta coat standing in their lab shaking hands with the CEO

What the market is finally beginning to realise, is that it is actually happening!!
CE approval and £1 bill order and the whole of UK / Europe knocking on their door for rapid test.
My Monday target price of 285 will easily happen today and let us see if our US buyer wants more this afternoon, then we have 310-15 as a closing price, with 340-5 Tuesday as a scenario of + 30 % profit margins will give us + 700p when order is in the bag.
Anyway remember the only thing one does NOT do is to SELL, sit tight and enjoy the ride.
Just like Arm holdings back in those days!!

Same size tomorrow, working order

Well, we got Friday ahead and indeed the Week end, one want to be mega long over the next couple of days, one would expect further news imminently , with Innova once again is a disaster.

A company that could work with Avacta:
News out today,
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company's current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.
"As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials. Single-use technologies, cell culture media and purification resins are among those in highest demand," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "These investments add significant capacity and regional redundancy to further bolster supply chains and help us better support customers as they accelerate the commercialization of lifesaving therapies and vaccines."

Post close prints have been very visible the last couple of days and I suspect we will continue to see this.
It is most likely a working order.
Quite normal in the city and with stocks from the AIM market.

Study just out, shows the growing concern there is with regards to B.1.1.7 in the UK and the B.1.351 in South Africa and their purported ease of transmission and extensive mutations in the spike protein.The same is the case with P.1. ( Brazil )
Conclusion is very much that both Johnson and Johnson and Novavax showed a significant drop in efficacy in South Africa.
Avacta once the company have full CE test approval, will be in huge demand on a global scale.

Sorry if this old news

Just out on BBC
There are concerns pupils could be forced to isolate unnecessarily due to inaccurate Covid test results when schools reopen in England on Monday

MSCI buying attracts other US buying

Interesting to see, that the UK government when appointed consultants to identify manufacturers of the Covid tests, the Government also invested in equipment, in order to expand production at the manufacturers, in order to meet a demand est. to be 2 mill a day.
Remember this puts Avacta in a incredible strong position as a test developer with a signed up manufacturing partners network and further expansion to be announced, according to the company.
When the announcement is out, the market will have to adjust earning estimates substantial above current numbers.The earnings uplift will produce long term quality share price growth, that is rarely seen in England.
As I have argued before, best thing out of Cambridge since ARM Holdings.
PS we must not forget overseas demand for Avacta LFT’s at a premium price relative to UK prices.

KKR quoted on Bloomberg, wanting to increasing spending on healthcare, remember the License deal Avacta made with Astrea, part of Gamma Science in Dec/2020, Gamma is a KKR vehicle, KKR coming back for more !!

Another day with interesting move

The minute Avacta are given green light, Innova will be pulled.
Any day now.